Jean-Yves Reginster

Division of Epidemiology, Public Health and Health Economics, University of Liège.
Liège, Belgium

Chair for Biomarkers of Chronic Diseases, College of Sciences, King Saud University.
Riyadh, Kingdom of Saudi Arabia

Jean-Yves Reginster M.D., Ph.D. is currently outstanding professor of Epidemiology, Public Health and Health Economics as well as professor of Bioethics and Societal Medicine at the University of Liège where he also serves as the Honorary Chair of the Bone and Cartilage Metabolism Unit. He is the Director of the Division of Public Health, Epidemiology and Health Economics at the University of Liège and Director of the WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging. He is visiting Professor at the Chair for biomarkers of chronic diseases, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia. He is an active researcher who has authored more than 900 publications, mainly dedicated to the pathophysiology, epidemiology, health economics, clinical and translational aspects of osteoporosis, osteoarthritis, frailty and sarcopenia. Prof. Reginster, among his other professional activities, is President of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Co-Founder and Board member of the International Osteoporosis Foundation (IOF), where he serves as President of the Committee of National Societies (CNS). He previously served as Adjunct Professor of Medicine at Georgetown University Medical Center, Washington DC, USA. He was the Belgian alternate member for the Efficacy Working Party at the Committee for Human Proprietary Medicines (CHMP) of the European Medicines Agency (EMA) where he acted as rapporteur/co-rapporteur for the guidelines for the registration of drugs to be used in the management of osteoporosis and osteoarthritis. He is also a former member of the Belgian Commission for Registration of Drugs and he also served at the Belgian Commission for Reimbursement of Drugs (Commission de Transparence). He acted as a Board Member of the Osteoarthritis Society International (OARSI).